IDEAS home Printed from https://ideas.repec.org/r/oxp/obooks/9780198529972.html
   My bibliography  Save this item

Economic Evaluation in Clinical Trials

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
  2. Kangethe, Anne & Franic, Duska M. & Corso, Phaedra S., 2016. "Comparing the validity of the payment card and structured haggling willingness to pay methods: The case of a diabetes prevention program in rural Kenya," Social Science & Medicine, Elsevier, vol. 169(C), pages 86-96.
  3. Hildegard Seidl & Matthias Hunger & Reiner Leidl & Christa Meisinger & Rupert Wende & Bernhard Kuch & Rolf Holle, 2015. "Cost-effectiveness of nurse-based case management versus usual care for elderly patients with myocardial infarction: results from the KORINNA study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(6), pages 671-681, July.
  4. Jennifer C Davis & Stirling Bryan & Carlo A Marra & Devika Sharma & Alison Chan & B Lynn Beattie & Peter Graf & Teresa Liu-Ambrose, 2013. "An Economic Evaluation of Resistance Training and Aerobic Training versus Balance and Toning Exercises in Older Adults with Mild Cognitive Impairment," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-9, May.
  5. Duncan Mortimer & Simon D French & Joanne E McKenzie & Denise A O′Connor & Sally E Green, 2013. "Economic Evaluation of Active Implementation versus Guideline Dissemination for Evidence-Based Care of Acute Low-Back Pain in a General Practice Setting," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-8, October.
  6. Helen Dakin & Sarah Wordsworth, 2013. "Cost‐Minimisation Analysis Versus Cost‐Effectiveness Analysis, Revisited," Health Economics, John Wiley & Sons, Ltd., vol. 22(1), pages 22-34, January.
  7. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
  8. Dorothea Kesztyüs & Anja Schreiber & Tamara Wirt & Martina Wiedom & Jens Dreyhaupt & Susanne Brandstetter & Benjamin Koch & Olivia Wartha & Rainer Muche & Martin Wabitsch & Reinhold Kilian & Jürgen St, 2013. "Economic evaluation of URMEL-ICE, a school-based overweight prevention programme comprising metabolism, exercise and lifestyle intervention in children," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 185-195, April.
  9. McCarthy, Ian M., 2016. "Eliminating composite bias in treatment effects estimates: Applications to quality of life assessment," Journal of Health Economics, Elsevier, vol. 50(C), pages 47-58.
  10. Theresa Tawiah & Kristian Schultz Hansen & Frank Baiden & Jane Bruce & Mathilda Tivura & Rupert Delimini & Seeba Amengo-Etego & Daniel Chandramohan & Seth Owusu-Agyei & Jayne Webster, 2016. "Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
  11. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
  12. Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore, 2013. "Acknowledging Patient Heterogeneity in Economic Evaluation," PharmacoEconomics, Springer, vol. 31(2), pages 111-123, February.
  13. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
  14. Nadia Yakhelef & Martine Audibert & Bruno Peirera & Antoine Mons & Emmanuel Chabert, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers halshs-01241824, HAL.
  15. Richard Grieve & Richard Nixon & Simon G. Thompson, 2010. "Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 30(2), pages 163-175, March.
  16. Melina Dritsaki & Felix Achana & James Mason & Stavros Petrou, 2017. "Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Sys," PharmacoEconomics, Springer, vol. 35(5), pages 501-515, May.
  17. Sebastian Hinde & Laura Bojke & Peter Coventry, 2021. "The Cost Effectiveness of Ecotherapy as a Healthcare Intervention, Separating the Wood from the Trees," IJERPH, MDPI, vol. 18(21), pages 1-13, November.
  18. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 1)," PharmacoEconomics, Springer, vol. 29(3), pages 189-198, March.
  19. Alexina J. Mason & Manuel Gomes & James Carpenter & Richard Grieve, 2021. "Flexible Bayesian longitudinal models for cost‐effectiveness analyses with informative missing data," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3138-3158, December.
  20. Manuel Gomes & Richard Grieve & Richard Nixon & W. J. Edmunds, 2012. "Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials," Medical Decision Making, , vol. 32(1), pages 209-220, January.
  21. Catherine Henderson & Martin Knapp & Ksenija Yeeles & Stephen Bremner & Sandra Eldridge & Anthony S David & Nicola O’Connell & Tom Burns & Stefan Priebe, 2015. "Cost-Effectiveness of Financial Incentives to Promote Adherence to Depot Antipsychotic Medication: Economic Evaluation of a Cluster-Randomised Controlled Trial," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-18, October.
  22. Lukasz Tanajewski & Matthew Franklin & Georgios Gkountouras & Vladislav Berdunov & Rowan H Harwood & Sarah E Goldberg & Lucy E Bradshaw & John R F Gladman & Rachel A Elliott, 2015. "Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM Randomised Controlled Trial)," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-20, December.
  23. Raymond Oppong & Sue Jowett & Tracy E Roberts, 2015. "Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-22, June.
  24. Nadia YAKHELEF & Martine AUDIBERT & Bruno PEIRERA & Antoine MONS & Emmanuel CHABERT, 2015. "Cost-utility Analysis of Vertebroplasty versus Thoracolumbosacral Orthosis in the Treatment of Traumatic Vertebral Fractures," Working Papers 201534, CERDI.
  25. Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise Hamers & Valentina Rupel & Renata Slabe-Erker & Thomas Davidson, 2016. "Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries," PharmacoEconomics, Springer, vol. 34(1), pages 59-76, January.
  26. J. Jayasekera & E. Onukwugha & K. Bikov & C. Mullins & B. Seal & A. Hussain, 2014. "The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer," PharmacoEconomics, Springer, vol. 32(2), pages 173-191, February.
  27. Manuel Gomes & Edmond S.-W. Ng & Richard Grieve & Richard Nixon & James Carpenter & Simon G. Thompson, 2012. "Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials," Medical Decision Making, , vol. 32(2), pages 350-361, March.
  28. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
  29. Aline Gauthier & Andrea Manca & Susan Anton, 2009. "Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials," PharmacoEconomics, Springer, vol. 27(12), pages 1017-1029, December.
  30. Becker, Christian & Holle, Rolf & Stollenwerk, Björn, 2015. "The excess health care costs of KardioPro, an integrated care program for coronary heart disease prevention," Health Policy, Elsevier, vol. 119(6), pages 778-786.
  31. Nicola E Stanczyk & Eline S Smit & Daniela N Schulz & Hein de Vries & Catherine Bolman & Jean W M Muris & Silvia M A A Evers, 2014. "An Economic Evaluation of a Video- and Text-Based Computer-Tailored Intervention for Smoking Cessation: A Cost-Effectiveness and Cost-Utility Analysis of a Randomized Controlled Trial," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-14, October.
  32. Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise F. Hamers & Valentina Prevolnik Rupel & Renata Slabe-Erker & Thomas Davidson, 2016. "Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries," PharmacoEconomics, Springer, vol. 34(1), pages 59-76, January.
  33. Batscheider, Ariane & Rzehak, Peter & Teuner, Christina M. & Wolfenstetter, Silke B. & Leidl, Reiner & von Berg, Andrea & Berdel, Dietrich & Hoffmann, Barbara & Heinrich, Joachim, 2014. "Development of BMI values of German children and their healthcare costs," Economics & Human Biology, Elsevier, vol. 12(C), pages 56-66.
  34. Maria Rubio-Valera & Judith Bosmans & Ana Fernández & Maite Peñarrubia-María & Marian March & Pere Travé & Juan A Bellón & Antoni Serrano-Blanco, 2013. "Cost-Effectiveness of a Community Pharmacist Intervention in Patients with Depression: A Randomized Controlled Trial (PRODEFAR Study)," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-10, August.
  35. G. Sagoo & S. Mohammed & G. Barton & G. Norbury & J. Ahn & C. Ogilvie & M. Kroese, 2015. "Cost Effectiveness of Using Array-CGH for Diagnosing Learning Disability," Applied Health Economics and Health Policy, Springer, vol. 13(4), pages 421-432, August.
  36. Kamran Khan & Stavros Petrou & Oliver Rivero-Arias & Stephen Walters & Spencer Boyle, 2014. "Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales," PharmacoEconomics, Springer, vol. 32(7), pages 693-706, July.
  37. Sabina Sanghera & Emma Frew & Janesh Gupta & Joe Kai & Tracy Roberts, 2015. "Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia," PharmacoEconomics, Springer, vol. 33(9), pages 957-965, September.
  38. Gemma E. Shields & Paul Clarkson & Ash Bullement & Warren Stevens & Mark Wilberforce & Tracey Farragher & Arpana Verma & Linda M. Davies, 2024. "Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature," PharmacoEconomics, Springer, vol. 42(7), pages 737-749, July.
  39. Rosemary J Korda & Grace Joshy & Ellie Paige & James R G Butler & Louisa R Jorm & Bette Liu & Adrian E Bauman & Emily Banks, 2015. "The Relationship between Body Mass Index and Hospitalisation Rates, Days in Hospital and Costs: Findings from a Large Prospective Linked Data Study," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-16, March.
  40. Paddy Gillespie & Eamon O’Shea & Andrew Murphy & Susan Smith & Mary Byrne & Molly Byrne & Margaret Cupples, 2012. "Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 429-443, August.
  41. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.
  42. Henry Glick, 2011. "Sample Size and Power for Cost-Effectiveness Analysis (Part 2)," PharmacoEconomics, Springer, vol. 29(4), pages 287-296, April.
  43. Mohsen Sadatsafavi; & Carlo Marra; & Lawrence McCandless & Stirling Bryan, 2012. "The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods," Health, Econometrics and Data Group (HEDG) Working Papers 12/24, HEDG, c/o Department of Economics, University of York.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.